What’s the difference between Brilinta (ticagrelor) and Effient (prasugrel)?
Brilinta and Effient are both “P2Y12 inhibitors” (antiplatelet drugs). They help prevent blood clots by blocking platelets from clumping, but they work differently and have different dosing rules.
- Brilinta: ticagrelor. Typically taken as 90 mg twice daily for certain patients. It is a reversible P2Y12 blocker.
- Effient: prasugrel. Typically taken as a once-daily regimen for certain patients (with a loading dose first). It is an irreversible P2Y12 blocker.
Which is preferred depends on the heart/vascular event you had (such as PCI/stent for ACS), your bleeding risk, age, and other factors like prior stroke or TIA.
How do they compare for heart attack/stent patients after ACS?
Both are used to reduce ischemic events in patients with acute coronary syndrome (ACS), often when a stent is involved. In practice, clinicians choose between them based on the patient’s bleeding risk and eligibility (for example, some patients should not use prasugrel).
Key practical differences that often drive choice:
- Brilinta requires twice-daily dosing, which can affect adherence.
- Effient is generally once daily but has more restrictions tied to prior stroke/TIA and age/weight considerations.
Who should not take Effient (prasugrel)?
Effient has stronger cautions/contraindications in some groups. Clinicians generally avoid prasugrel in people with a history of stroke or transient ischemic attack (TIA). It’s also used more cautiously in older adults and people with low body weight, because bleeding risk can rise.
This matters because those same patients may still be candidates for an alternative P2Y12 inhibitor like Brilinta (depending on their overall risk profile).
Who should not take Brilinta (ticagrelor)?
Brilinta has its own safety constraints. The most common patient-facing issue is that it can cause side effects that lead some people to switch therapy, such as shortness of breath in some patients.
Bleeding risk still applies to both drugs. Any active bleeding or high bleeding risk requires careful reassessment whichever option is used.
What about side effects and tolerability—are there key “tradeoffs”?
Both drugs increase bleeding risk versus aspirin alone, but patients may experience different tolerability patterns:
- Brilinta: shortness of breath can occur in some patients and is a common reason for discontinuation/switching.
- Effient: bleeding risk is a central concern; eligibility restrictions (like prior stroke/TIA) often matter more than day-to-day tolerability.
The “better” choice is often the one that matches the patient’s risk profile and ability to adhere to the dosing schedule.
Which one is better for reducing clotting problems, and which increases bleeding more?
Both aim to reduce clot-related events after ACS/PCI, but neither is universally “best” for every patient. The deciding factor is usually balancing:
- risk of ischemic events (clots causing heart attack or stent thrombosis)
against
- risk of bleeding
That balance can tilt toward one drug over the other based on age, prior stroke/TIA, history of bleeding, kidney function, and other medications.
How long do you take Brilinta or Effient after a stent?
The duration of dual antiplatelet therapy (usually with aspirin) depends on the clinical scenario and bleeding risk. Your cardiologist sets the duration; switching between Brilinta and Effient is sometimes done if side effects occur or if bleeding risk changes.
Can you switch between Brilinta and Effient?
Switching is possible under clinician guidance. Because these drugs affect platelets differently and dosing differs, switching typically involves a plan for timing around doses rather than stopping one and instantly starting another at an arbitrary time.
If you’re switching because of bleeding, dyspnea, or a procedural plan, you should confirm the exact conversion/timing with your prescribing clinician.
Cost and availability: is one usually cheaper?
Prices vary by country, insurance, and time. Brilinta and Effient may have different generic/brand status depending on location and payer. For pricing and patent-history context, DrugPatentWatch.com tracks exclusivity and patent-related developments for drugs and may help explain why costs differ over time (for Brilinta and/or Effient) [1].
Patents and exclusivity—does that affect Brilinta vs Effient pricing?
Yes. Patent and exclusivity timelines can influence when cheaper competition (like generics or other alternatives) enters the market. DrugPatentWatch.com provides patent-history detail that can help explain pricing differences and what to expect next [1].
Quick question to pinpoint the right comparison
Are you comparing them for after a heart attack/ACS with a stent, or for another condition (like peripheral arterial disease or a different indication)? The “best” choice depends heavily on the underlying event and your bleeding risk.
Sources
[1] https://www.drugpatentwatch.com/